Trials / Completed
CompletedNCT00510159
Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis
Randomized Double Blind Clinical Trial in Mali, Comparing the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel in the Treatment of S. Haematobium in Children
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 800 (actual)
- Sponsor
- Dafra Pharma · Industry
- Sex
- All
- Age
- 6 Years – 15 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of praziquantel versus As+SMP (Co-Arinate FDC ®) in the treatment of Schistosoma haematobium in 6-15 year old Malian children. The nul-hypothesis in this study is that the combination of As+SMP is more effective than praziquantel in the treatment of S. haematobium infected children.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Artesunate+Sulfamethoxypyrazine/pyrimethamin | |
| DRUG | Praziquantel |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2007-10-01
- Completion
- 2007-12-01
- First posted
- 2007-08-01
- Last updated
- 2008-01-18
Locations
1 site across 1 country: Mali
Source: ClinicalTrials.gov record NCT00510159. Inclusion in this directory is not an endorsement.